Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. - Wikidata - awgldk - TriplyDB

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

http://www.wikidata.org/entity/Q37378270

about

MR-less surface-based amyloid assessment based on 11C PiB PET Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease Beta-amyloid deposition and the aging brain Reliability of two-dimensional and three-dimensional pseudo-continuous arterial spin labeling perfusion MRI in elderly populations: comparison with 15O-water positron emission tomography.Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.In vivo validation of reconstruction-based resolution recovery for human brain studies.Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET Profiling of hepatic clearance pathways of Pittsburgh compound B and human liver cytochrome p450 phenotyping.Cerebral amyloid PET imaging in Alzheimer's disease.Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.Contributions of imprecision in PET-MRI rigid registration to imprecision in amyloid PET SUVR measurements.(18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids.Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine.Small-molecule PET Tracers for Imaging Proteinopathies.Amyloid and its association with default network integrity in Alzheimer's disease.Blood-brain barrier P-glycoprotein function in Alzheimer's disease.An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease.

P2860

Q24618963-F85D7B02-868D-497C-AF29-8DA0CF502FAE Q27009411-042550F1-24CF-4A75-9A9A-24296AF6264A Q28264556-78BA7806-E35E-4242-82B7-3DFF42E444E7 Q30667035-88DDE683-514E-4F2C-866B-C0AA9FE0A05F Q33747987-FA271C77-96C5-42E9-93D2-ABBFA4DC8045 Q34170801-DC0050B4-41AE-43E0-9013-D1D6AAFEFDD6 Q34606568-87E968D8-A197-47D9-873C-E972265777A1 Q34989647-85A8F327-FA47-44C2-A640-4397E5CDB77E Q35600979-B531EEE6-1DF1-48AA-B171-74C4D54BAED1 Q36514158-FB09AA4E-4459-4313-8498-139F3E8460A9 Q36690141-E77A90A6-C69A-4D1F-85CE-314E825A2FD0 Q37459083-06B951CE-605C-45CD-BE3F-04825CF297E0 Q37647518-87AB963F-6EF5-4F75-9C72-D5C9B39EF426 Q38692086-5FEEC347-1DCA-486B-B31C-267EA3CE2BDE Q38712820-B6A0ADF8-B243-40E4-A507-63AC2B174480 Q44414803-3E033BD0-C358-4A21-B542-7B6F2487AE02 Q47926474-AF35E332-34D7-4F8A-9A42-72268A19D820 Q48254113-423AFDF4-E3AC-4111-9382-F7EC59C9AF28 Q50778486-65B0A16D-A316-4960-A6F8-C4A42E45814C Q53397430-CF26A5D2-B269-4D4E-A0A2-55291D0ABF02

P2860

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

http://www.wikidata.org/entity/Q37378270

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

@en

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

@nl

type

label

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

@en

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

@nl

prefLabel

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

@en

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

@nl

P1433

Q37378270-CC844A04-4ABF-4355-8964-BA8D5859075E

P1476

Q37378270-C7E0F077-D457-4769-88EF-334417A3390C

P2093

Q37378270-5B3F30B8-3CD5-4DC2-86CD-FE535F295870

Q37378270-66C4AC0B-CC86-4E56-AFA4-AA903EB4CFC7

Q37378270-85053316-2D5A-4BC3-ACD4-CB9300FF1933

Q37378270-D963BA24-7528-44F2-BF18-DF753577B9C9

P2860

Q37378270-049DA4DA-EFC7-46E4-9B83-F19EE95EF0A5

Q37378270-082DBCFC-3AC9-430F-B605-D904612AF4B7

Q37378270-0FE0CA73-4660-49FF-948E-79F999B060ED

Q37378270-1909B299-73A7-4A38-BC11-51B9B48BDF6D

Q37378270-19D7B04B-F5BA-4DF2-AC24-8748A5FFA5A8

Q37378270-3E9BA743-C5ED-4B1F-995B-E65B795792DF

Q37378270-3F26B5FE-0EC2-4A65-A9BA-66CD4FFA536E

Q37378270-40FFEA4F-D60E-4FD3-AD3A-767571B21B31

Q37378270-4541E8E3-C01E-48BB-9CFA-24C62D188114

Q37378270-4A109E74-5764-4DEB-B2FF-20219DA93895

P2888

Q37378270-BDBF353B-0B01-43CB-B0FC-B0007B5A59AE

P304

Q37378270-82BA4079-885C-44CE-988D-FF4998DA95D0

P31

Q37378270-6683829C-A2F6-4982-90F4-97211B5A7BA3

P356

Q37378270-162E3F75-860A-4D62-8757-D5A32D548803

P433

Q37378270-6E96BC2D-98B4-4689-9223-9A45DD85456C

P478

Q37378270-DB3B5F9E-A5E8-4EDB-827E-74942F98ACCD

P50

Q37378270-08D070E4-931F-42CD-B02A-2B7CFC5CFE0F

Q37378270-4FC918D8-CED6-4E97-93D9-E9913C86F6C7

Q37378270-789A2A13-6B46-4289-865F-DC6A35D20FAB

Q37378270-BA0276F8-B724-400D-B015-8DB140528D66

P577

Q37378270-851A0C7A-0821-47A9-8F2F-432C7B65F9EE

P5875

Q37378270-D64AC44F-1287-4D4F-A807-2E5A6725E842

P698

Q37378270-C91EE421-1765-4B8F-AD59-9315D57FA333

P921

Q37378270-DFAC81ED-A105-404A-9AC1-F67F2C736797

P932

Q37378270-767D5E5F-0D93-4AA4-9B90-1334FFE6BCB5

P356

S00259-009-1129-6

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

@en

P2093

Bart N M van Berckel

http://www.w3.org/2001/XMLSchema#string

Gert Luurtsema

http://www.w3.org/2001/XMLSchema#string

Maqsood Yaqub

http://www.w3.org/2001/XMLSchema#string

Nelleke Tolboom

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Neuropathological stageing of Alzheimer-related changes

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.

Positron emission tomography compartmental models.

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees

Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease.

Current progress in beta-amyloid immunotherapy.

Distribution volume ratios without blood sampling from graphical analysis of PET data.

P2888

s00259-009-1129-6

P304

1629-1638

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-009-1129-6

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Philip Scheltens

Albert D. Windhorst

Ronald Boellaard

Adriaan A Lammertsma

P577

2009-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24346686

http://www.w3.org/2001/XMLSchema#string

P698

19384547

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

2758198

http://www.w3.org/2001/XMLSchema#string